Compare iShares MSCI Canada (TSX) (EWC) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Illumina, Inc. — how do they compare? iShares MSCI Canada (TSX) trades at $58.3 (market cap $7.14B), while Illumina, Inc. trades at $264.24 (market cap $40.43B). The key difference: Illumina, Inc. is far larger — about 5.7× iShares MSCI Canada (TSX)'s market cap, and Illumina, Inc. is trading nearer its 52-week high, iShares MSCI Canada (TSX) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 57 Days and Illumina, Inc. for 83 Days on average.
| EWC | ILMN | |
|---|---|---|
Market Cap | $7.14B | $40.43B |
Volume | 2,496,812 | 2,948,626 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $293.69 |
52-Week Low | $49.72 | $91.00 |
Typical Hold Time | 57 Days | 83 Days |
Enterprise Value | — | $41.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC is trading at $57.94, down 2.1% with a bearish technical signal as moving averages indicate selling pressure while oscillators remain neutral. The stock shows oversold conditions with RSI readings below 30, suggesting potential for near-term bounce. Recent news highlights Canada's trade tensions with the US and potential EU associate membership discussions creating market uncertainty.
The outlook remains cautious given trade policy risks and technical weakness, though oversold conditions may provide short-term opportunities. Key risks include US-Canada trade disputes and economic sensitivity to external shocks, while potential EU alignment could offer diversification benefits if negotiations progress favorably.
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
